Answers are grounded in this paper and cite their sources.
Requiring regional or in-country confirmatory clinical trials before approval of drugs already approved elsewhere delays access to medicines in low- and middle-income countries and raises drug costs. Here, we discuss the scientific and technological advances that may reduce the need for in-country or in-region clinical trials for drugs approved in other countries and limitations of these advances that could necessitate in-region clinical studies.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: